Reasons for Declining to Enroll in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania by Tarimo, Edith A. M. et al.
Reasons for Declining to Enroll in a Phase I and II HIV
Vaccine Trial after Randomization among Eligible
Volunteers in Dar es Salaam, Tanzania
Edith A. M. Tarimo
1,2*, Anna Thorson





1Division of Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden, 2Department of Nursing Management, Muhimbili University
of Health and Allied Sciences, Dar es Salaam, Tanzania, 3Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania,
4Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Abstract
Background: Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the efforts to
ultimately develop a vaccine that can prevent new HIV infections. Following recruitment, some randomized individuals
decline to be enrolled in an HIV vaccine trial. The reasons for such a decision are not well known. This article describes why
individuals who were randomized in a phase I and II HIV vaccine trial in Dar es Salaam, Tanzania declined to be enrolled.
Methods: Face-to-face interviews were conducted with 14 individuals (7 men and 7 women). Repeated readings of the 14
interview transcripts to look for reasons for declining to enroll in the trial were performed. Data was analyzed using the
content analysis approach.
Results: Informants expressed fear of the outcome of an experimental HIV vaccine in their lives. Unlike women, some men
were concerned over the effect of the vaccine on their reproduction intentions. Women were concerned about the
unknown effects of the vaccine in their bodies. Also, to a large extent, informants faced resistance from significant others
such as fiance ´es, parents, relatives, and friends. Women were influenced by their potential intimate sexual partners; men
were forbidden by their parents, and mothers had the most influential opinion.
Conclusions: Fear of the negative outcome of an experimental vaccine and resistance from significant others are the main
reasons for declining to enroll in the HIV vaccine trial among eligible volunteers after randomization. The resistance from
the significant others provides valuable guidance for designing future trials in Tanzania; for example, expanding the HIV
vaccine trial education to the general population from the onset of the trial design.
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Introduction
Throughout the world, only one HIV vaccine candidate has
shown a modest efficacy in a phase III trial [1]. Multiple trials are
needed to develop an eventual effective HIV vaccine. However,
conducting trials is difficult for several reasons including challenges
experienced during recruitment, enrollment, and retention of
study participants [2,3,4,5,6,7,8,9,10]. In previous studies, partic-
ipants were not ready to take part in an experimental HIV vaccine
because of fear of becoming infected with the HIV virus and
mistrust of governments conducting the trials [4,7,8,10,11].
Women were concerned about the potential effects of HIV
vaccine trial on their reproductive health [10,12,13]. Also they
sensed that taking part in the trial would bring conflicts in their
parental roles, negotiating safe sex with male partners, worries
about being stigmatized, and being discriminated against [10].
In order to increase the retention of future volunteers, it is
important to understand reasons that influence eligible individuals
not to enroll in HIV vaccine trials. Globally, few studies have
focused on whypeople decline to enroll in HIVvaccine trials[6,14].
In these studies, trial duration, concerns about false-positive HIV
test results, side effects and negative reactions from partners were
commonly cited as reasons for declining to enroll in the HIV
vaccine trials. In one study, trial duration was a factor that
influenced individuals not to complete follow-up visits during the
trial[5].These studieswere conductedinthe highincomecountries.
The sub-Saharan African countries have the highest HIV infection
rates and disease burden, but fewer HIV vaccine trials have been
conducted than in the United States and Europe [15,16].
Conducting trials in low income countries is equally important
given the burden of HIV infection rates [17], and retention of those
who volunteer for the trials is therefore crucial to maximize use of
resources [18]. Little is known from Africa about why individuals
enroll in HIV vaccine trials and subsequently withdraw.
Tanzania is among the low income countries conducting Phase
I and Phase II HIV vaccine trials [16]. During the recruitment
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before the first vaccination [actual enrollment]. The term ‘decline’
in this study is defined as an act of a screened, eligible and
randomized volunteer not showing up to receive the first vaccine
[DNA or placebo] dose within 30 days after randomization.
According to the trial plan, the first vaccination was scheduled 14
days after randomization. Therefore, the purpose of this study was
to understand why some individuals who were randomized in a
Phase I and II HIV vaccine trial (HIVIS03) in Dar es Salaam,
Tanzania, subsequently declined. This study produces knowledge
of reasons for declining to enroll in the HIV vaccine trial by using
the content analysis approach [19].
Materials and Methods
Ethics statement
This study draws material from a randomized double-blind
phase I and II HIV vaccine trial research project conducted
among healthy volunteers in Dar es Salaam, Tanzania [16]. The
project was approved by the National Institute for Medical
Research (NIMR) Ethics Committee which offered a letter(s) with
reference number NIMR/HQ/R.8a/Vol.IX/410. This approval
was for the whole HIV Vaccine Trial project protocol that
included follow up of the study participants and documentation of
the reasons for withdrawal from the study. In the present study,
after describing the purpose of the study, the first author reminded
the potential informants of their signed consent before they
declined that included agreement to be followed up. All potential
informants consented for tape-recording of the interviews,
although one interview was not recorded because the environment
was too noisy. Informants were not paid for their participation.
Note: In detail, potential volunteers signed informed consent,
part 1 before they were screened for enrollment in the trial. The
screening involved: clinical history and examination; HIV
counselling and testing; laboratory tests that included blood tests
to screen for syphilis and hepatitis B infections, haematology and
clinical chemistry as well as urine collection for pregnancy test
among females. Two weeks later, they signed informed consent,
part 2 to confirm their enrollment in the HIV vaccine trial and
follow up if they skipped the planned schedules. This procedure of
signing two parts of the informed consent was stated in the original
project protocol. Also, during this second visit all laboratory results
in line with fulfilling the inclusion criteria were reviewed and the
volunteer was assessed to make sure that he or she understands the
objectives of the study.
Informants
All informants participated in a series of educational sessions on
HIV, AIDS and HIV vaccine trial concepts and procedures that
were conducted from 2006 to 2007 among potential volunteers for
the HIV vaccine trial [13,20].
A total of 177 individuals were screened for the trial between
February 2007 and February 2008. Of these, 89 (50.3%) were
ineligible on a medical basis after thorough medical and laboratory
screenings were done. Nine (5.1%) were eligible but were not
randomized for the study because the enrollment had been closed;
79/177=46.6% were eligible and were randomized to enter the
trial. However, 19/79=24.1%, 12 men and seven women,
declined to enroll after randomization. Thus, 12/57=21% men
and 7/22 =32% women declined enrollment after randomiza-
tion. Sixteen out of 19 (9 men and 7 women) were accessible and
were contacted 1–23 months after declining for this follow up
study. The first author contacted the individuals through their
mobile phones, briefed them about the aim of the present study,
and asked for their willingness to discuss with the researcher (first
author). Of the 16 individuals, 2 men refused to take part in this
study without explanations. The rest, 14/19=74% agreed, were
accessible, chose to meet the researcher at their workplace and
participated in this study fully (See figure 1).
Study design
While informants were purposively selected because they are
‘information rich’ for the phenomenon of interest [21], the sample
was convenient in the sense that it was all inclusive of those who
declined to enroll in the trial and accessible to take part in this study.
Data collection
Face-to-face interview. Fourteen informants were inter-
viewed about the reasons for declining to enroll in an HIV
vaccine trial after randomization. The first author who was also part
of the recruitment team conducted all interviews in privacy within
the individuals’ workplace, using an interview guide. The guide
consisted of the following statements: ‘I understand you are among
the volunteers who were randomized in an HIV vaccine trial;
however,lateryoudecidednottocontinuewiththeplannedvisitsfor
the vaccinations. Can you explain to me the reasons for not
continuing with the scheduled vaccinations?’ This was followed by
probing set of questions according to the responses. After the first 8
interviews, the guide was expanded to include their suggestions to
improve future recruitments for HIV vaccine trials. Thirteen
interviews were audio-taped, lasted for 10–30 minutes each, and
were conducted between April 2007 and November, 2009. One
interview was not tape-recorded because the environment wasnoisy.
Analysis
A research assistant transcribed the audio-tapes word for word.
Another research assistant translated all transcripts from Kiswahili,
Tanzania’s national language to English. The translations were
checked by the first author (EAMT) who speaks both languages.
EAMT listened to the audiotapes and at the same time read all
transcripts to ensure that there were no parts of the discussions lost
during transcription. She repeatedly read all interview transcripts to
understand what each participant communicated about the topic.
The data was analyzed using a content analysis approach as
suggested by Graneheim [19], and the results were mainly manifest
in content. At the beginning, the meaning of each participant’s
response about declining was coded and written on the margin of
the transcript. The text was divided into sentences and paragraphs
(meaning units) that were condensed, abstracted and labelled with
codes(seeexampleinTable1).Thecodesweresortedmanuallyinto
subcategories, categories, and one theme emerged. The categories
and subcategories were discussed, negotiated and revised by the first
and the last author[AK]. We used quotes to ensurethat informants’
views are reflected in the paper, and for the purpose of this
interview, informants’ sex and serial numbers are assigned in the
text to protect their identity.
Results
Description of the informants
Seven men and seven women were interviewed. Their ages
ranged between 20–38 years, with an overall mean age of 28 years.
Five men identified themselves as single and without children.
Two men were married, and two had children during data
collection. Three of the women were married with one to two
children each, and one was a single parent. Thirteen of the
informants had attended four years of secondary education and
one had completed seven years of primary education.
Enrolling in HIV Vaccine Trial
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The reasons for declining to continue participation in the HIV
vaccine trial as described by informants in this study are under one
theme: ‘Perceived fear towards enrolling in an HIV vaccine trial’.
This theme included two categories. The first category, ‘Personal
fear of the HIV vaccine’, brings attention to the possible side
effects that would harm the informants in different ways and at
different periods. The second category, ‘Resistance from the
significant others’, highlights discouragements from other people
who pointed to the belief that the vaccine is harmful and would
interfere with social bonds.
Personal fear of the HIV vaccine
Potential side effects of vaccine in the reproduction
continuity. Even though all participants expressed enthusiasm
and free will to enroll in the HIV vaccine trial at the time of
consent, most of them declined later because of fear. Some men
stated that they intended to continue with the trial, but they had to
stop before receiving the vaccine because of fear of the effect that
the vaccine could have on their reproduction intentions. They
were worried about a series of rules on ‘dos and don’ts’ that were
issued by the researchers. They believed the vaccine might be
harmful in their reproduction continuity, and the trial would mess
up their marriage relationship. One participant expressed the fears
as follows:
…they [researchers] presented it in this way: ’you are not
supposed to do sexual intercourse without a condom for a
certain period. Then a woman should not conceive or get
pregnant. I mean you are not supposed to give birth in that




Description close to the text Codes
I didn’t understand, we [researchers and I] don’t even
know for how long that vaccine will stay in the body!
You set insurance of two years, but I may get any problem
after two years and think that, it is because of that
vaccine. I will go to hospital and given panadol and
asprin and will not get proper treatment!
Researchers and I don’t understand
how long the vaccine will stay in
the body; I may get problems when
insurance is over and will be not
get proper treatment
Fear of side effects
Unsure of health services after the trial
Prerequisite for a prolonged health insurance
doi:10.1371/journal.pone.0014619.t001
Figure 1. Recruitment of the study informants.
doi:10.1371/journal.pone.0014619.g001
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and stay in our body for a long time it will cause harm…
That is the main reason for us to discontinue, and saying
that ‘even if you will be given that vaccine will be there a
feeling in your marriage relationship? It will only bring
disturbance!’ (Informant 3, man)
A newly married man was mostly concerned with the trial rules
that seemed to interfere with his marriage intentions. He was
worried about the rules, given that he just got married, not having
a child as yet, and the vaccine was on an experimental basis. He
decided to postpone enrolling and gave priority to having a child.
He narrated:
First, it was the vaccine on trial, and we were told that if we
accept to participate in that program we are not supposed to
engage in penetrative sexual intercourse with any woman for a
year to avoid its effects in pregnancy. At that time, I was doing
another attempt in order to get a child! (Informant 12, man)
On the contrary, women stated that pregnancy restriction was
not a problem, but they declined because of other types of fears.
One woman confidently understood that enrollment in the trial
cannot interfere with her reproduction capacity because she
trusted the information given about the trial safety on reproduc-
tion. She believed she could get a child after the trial. She
reflected:
We asked in one of the seminar that if a woman participates
in the vaccine what happens … They [researchers] said
there will be no problem… but in this period she is not
supposed to conceive. In that case, I have seen that I will get
a child afterwards [after completing the vaccinations in the
trial] (Informant 11, woman)
Another woman with two children added that, her reason for
declining was not fear of vaccine’s effect on the reproduction, but
other possible side effects:
I didn’t have that worry of being infertile because of the
vaccine … I may get another child if I wish … but my worry
is that I don’t know what will be the side effects of that
vaccine in the body! (Informant 14, woman)
In addition, the perceived negative effects of the HIV vaccine
trial were multiple as described in the following section.
Possibilities of unknown negative effects of the vaccine in
the body. Some women said that they became nervous about
the vaccine’s side effects in different ways. One woman declared
that she was in the forefront in the HIV vaccine trial study,
motivating colleagues to take part, but she stepped down after the
death of her sister [the sister was not in the trial]. She stated that,
the knowledge she gained about the trial could not overcome her
fear after the funeral of her late sister. Nevertheless, she felt
impassive in her fear:
I did all the screening procedures. Everything was good and
I understood everything … my sister passed away while I
was getting prepared to get the first vaccine …. Surprisingly
after the funeral, I was tense and deeply felt that I should not
continue to enroll in the trial … (Informant 8, woman)
When probed to explain more, she insisted that she couldn’t
understand what was happening in her body [mind]. She
elaborated:
Do you know something that makes you cautious not to do
something for no obvious reason? That was what happened
to me… my fear is inside my heart. I just feel I cannot
continue with the trial! (Informant 8, woman)
Another woman who was also preparing to get the first
vaccination described her fear after seeing a colleague (man)
excessively vomiting a day after the vaccination. She heard
rumours all over the workplace: ‘Those are the vaccine’s side
effects! [Some colleagues insisted]’. Although, she recalled that
after medical consultation (not at the trial clinic), it was clear the
cause of the vomiting was excessive alcohol taking, she did not
believe in that explanation. She was worried, but she felt
responsible and need to be nice to the trial team:
… a nurse from Muhimbili [study nurse at the trial clinic]
called me, and I had nothing to say except promising that I
would go to the clinic. I don’t know if it would be
appropriate to tell that I would not go! (Informant 7,
woman)
Even though she had already made up her mind not to continue
with the trial, she experienced guilt. While recalling the politeness
of the trial team, she said:
You know what I am ashamed of is to meet such incredible
people at the clinic; stating that I don’t want to proceed with
the trial! I remember doctors, nurses, and counsellors; the
way they handled me so friendly with a cup of tea with milk
….’’ No, but my heart doesn’t encourage me to continue
[proceed with the trial] … (Informant 7, woman)
On the vaccination day, another woman reversed her decision of
receiving the vaccine because of personal fear of not involving her
mother. Thus, she wanted to postpone the vaccination in order to
consult her mother first. However, she felt that the service providers
at the trial clinic did not support her concern accordingly. So she
quit and explained that her mother was supposed to know before
shereceivedthe vaccination.Sheinsistedthathermotherwasavery
important person in her decision. She explained:
When I told them [service providers at the trial clinic] that I
wanted to talk to my mother first before I get the vaccine,
they became impolite …I mean they failed to convince me
at the last point … I told them that I’m going to talk to my
mother because she is second after God. So, if she accepted,
I would accept too (Informant 9, woman)
Each of these women expressed fear in different ways, but
importantly, the fears reversed their decisions to enroll in the HIV
vaccine trial.
Uncertainty about the insurance during and after the
trial. Informants continued to fear of vaccine outcome in both
short and long terms and in case the trial fails and causes harm.
They were not satisfied with the information given about the
insurance, and particularly, the length of health insurance that was
planned to end after the trial. They doubted about their future in
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the uncertainty about the insurance:
They [researchers] are saying this program will end next
year… if it [vaccine] brings side effects and the health
insurance has expired, perhaps I will be a victim. Now, I
don’t know which side will I be, which group will I belong
to? You see, things like these can make a person doubt about
it (Informant 3, man)
Another informant believed the information about the trial
safety and insurance was not convincing at all. She feared that the
vaccine could have effects that were not known to anybody, even
to the researchers themselves. She imagined that the trial could
possibly involve health related risks and felt the need for an
extension of the planned health insurance:
I didn’t understand …., we [researchers and I] don’t even
know for how long that vaccine will stay in the body! You set
insurance of two years, but I may get any problem after two
years and think it is because of that vaccine …insurance
[continuation of health insurance] is very important
(Informant 14, woman)
In addition, this informant expressed fear of joining in the trial; the
trial that did not even guarantee life insurance. Her worry was
exacerbated by the possibility of death because of vaccine side effects
and leaving the family unsupported. She felt that life insurance was
among the prerequisites for her to enroll in the trial. She stated:
Even if I get affected to death, then I leave the family. My
family should benefit to some extent such as children getting
school fees, but they [trial team] said there is no such kind of
insurance; this is just the issue of voluntarism. That thing
really created more doubts (Informant 14, woman)
Informants insisted on the need for adequate health and life
insurance for the volunteers in the trial. Also, some claimed that
the paying of 20USD to cover travel and time cost which was
allocated for the enrolled volunteers was not enough. One
informant suggested for an increase to cover special meals in case
a volunteer gets sick during the trial.
Mistrust of the researchers’ intentions. Somehow,
informants were suspicious about the researchers’ intentions given
that they were informed that the vaccine might have unknown side
effects. However, they did not believe the safety part of the vaccine
although it was explained by the researchers during the seminars.
One informant believed that the researchers were afraid of taking
part in the trial because of uncertainty about the trial:
It may have negative effects in the future. You [researchers]
insisted that the vaccine has no side effects [serious side
effects] but it is not true. One day I asked one of you who
facilitated the seminar that ‘who gets an HIV vaccine among
you?’ They said ‘we are not allowed to get that vaccine
because we are service providers.’ Don’t you see that you are
avoiding something? (Informant 14, woman)
Overall, these personal fears were diverse, and each informant
had a way of expressing his or her concern(s) which were either
single or multiple according to individuals’ descriptions.
Resistance from significant others (fiance ´e, parents,
relatives and colleagues)
Uncertainty about the close relationships. Although most
informants expressed enthusiasm to enroll in the trial; they realized
that a final decision had to receive the approval of significant others.
They voiced that their significant others did not trust the content of
the HIV vaccine. Therefore, they were discouraged from
continuing with the trial. Under such circumstances, informants
were forced to weigh whether to enroll in the trial against the
opinions of the significant others. Consequently, both men and
women feared breaking the existing social bonds because of
enrolling in the trial. Women were mostly influenced by the
intimate sexual partners. One woman was indirectly warned by her
fiance ´e and she couldn’t force him. She narrated:
It doesn’t mean that I don’t want to proceed with
vaccination process. My fiance ´e is the cause because when
I was about to get the first vaccination, I described to him…
he kept on saying: ‘wait a little bit, I have to think critically
and then I will let you know’. And this has been a long time
since he commented… That is the main obstacle (Informant
2, woman)
Another informant explained that she declined because her
fiance ´e forbade her to enroll straight away. Although she felt bad
about it she could not force him in order to protect their marriage
intentions. She said:
…my fiance ´e did not accept it completely! And he warned if
I enroll in the trial our relationship would end; even though
he had already paid a dowry, he would cancel our marriage
plans… I felt bad because I had already committed myself
with that relationship and I saw there is no need to force him
(Informant 11, woman)
Another woman (informant 5), who had a six-year-old child
stated she was forbidden by her husband to enroll when she was
just about to receive the first vaccination. She recalled that her
husband supported her in the beginning but not in the end. She
suspected the husband had desired to have a second child.
Responsibility to care for parents. Unlike women; men
expressed the need for consensus from their parents to continue
with the enrollment in the trial. However, they stated that they
were cautioned and reminded about their responsibility to the
aging parents. They received series of warnings from their parents
including mistrust of the imported vaccine. Under such opinions
and warnings, young men hesitated to argue with their parents.
Finally, they realised that enrolling in the vaccine trial was not the
best. The following quote reflects the dialogue:
I told my parents but they told me that: ‘Do you know we
are getting old now? … … wazungu [white skinned people]
brought these things [vaccines] to you, and you are
searching for death …You have to tell me the day when
you are going to get that vaccine, I mean you have to tell
me! Don’t go there before telling me’ [the mother warned].
She insisted that I should not go without telling her. I didn’t
know her intention of doing that (Informant 3, man).
Also, other men realised that their mothers were suspicious
about possible negative outcome of the trial; the outcome that
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responsible and the need of ‘being the insurance for their parents’
despite the fact that they were interested to enroll in the trial. The
following discourse explains:
When I told my mother about that [vaccine trial], in brief
she was shocked! … On top of that I’m the only son remain
in our family; the rest passed away… She insisted I should
stop where I reached. That means I should stop. I asked her
why? She said: ‘that is what I am saying, if you are going
against, it will be your decision and what I have told you,
that is it’. So, I thought of that… That was the end of the
exercise, but I was not happy to stop there (Informant 13,
man)
They added that parents were against their intention to enroll in
the trial, and were obliged to follow their opinions:
… They [parents] told me that: ‘As your parents, we don’t
agree with your idea…; if you don’t listen to us; fine’… They
cautioned me not to continue with my mission and insisted:
‘we ask you to discontinue with those things, and if you
object, just go and whatever happens will be up to you’.
Therefore, I had to listen to my parents (Informant 6, man).
In addition they faced resistance from their fathers. A married
man with two children described how he was convinced by his
father. Following his father’s advice, he decided to drop his
intention to enroll in the trial at the last minute. He said:
What hindered me is him [father] … he listened to it and
then said ‘it is good but most of the time that kind of exercise
[trial] brings effects to people in future… So long my father
told me about that I saw that there is no reason to
participate on that vaccine. That is why I decided to quit …
(Informant 10, man)
Other men described how they struggled to sellthe idea of thetrial
to their families, but all efforts ended in vain. One informant
recognized the importanceof hisparentsas the main advisors,and so
hadtoobeytheiropinionsdespitehisenthusiasmtoenrollinthetrial:
It is parents who advised me. I was ready to get that vaccine
but my family queried: ‘Can’t this vaccine cause HIV
infection in your body?’ I told them, it will not, but my
mother warned me: ‘You should stop, stop continuing with
that’… As you know, they [parents] are core advisors
especially to me at this time (Informant 1, man).
Another man expressed that the family, particularly his brother
did not support his decision to enroll in the trial at all. He
suspected that the brother feared that he would deliberately die
because of introducing a virus through the vaccination:
… I explained it to my relatives but they didn’t believe it! …
They started telling me that ‘you protect yourself for a long
time and then you go to be infected with HIV!’ … My
brother opposed and said: ‘you are still young; you are going
to lose your life for such things!’ I explained but he did not
understand (Informant 4, man)
Generally, the collective support sought from the close members
of the family reversed the informants’ mind-set. At moments of
increased different opinions, informants simply lost control over
their enthusiasm and decision to enroll in the trial.
Discouragement from colleagues and friends. In
addition, informants reported discouragement from outside the
family; especially, from the colleagues and friends who posed
queries about the safety of the HIV vaccine trial. Such
discouragements reversed informants’ decisions to continue with
the trial, and given that they had no evidence of seeing a volunteer
who had received a similar kind of vaccine. They reflected on the
warnings from colleagues who warned them right after the HIV
vaccine seminars that enrolling in a vaccine trial will be dangerous
in the future. This opinion forced some informants to decline.
Informants recognised that most of the colleagues who were
discouraging them were not exposed to the HIV vaccine trial
education sessions. Nevertheless, they were forced to weigh their
decision against opinions of others because they relied on them for
socialisation. Thus, they illustrated moments of uncertainty
whether to join in, but the influence of friends overpowered their
decision.
Discussion
This study illustrates that informants declined to enroll in the
HIV vaccine trial because of single or multiple reasons. They
feared the potential side effects of an experimental vaccine in their
lives, such as interference with reproduction intentions; possibil-
ities of harmful effects, to the extreme death in absence of life
insurance. This is especially so in the absence of a life-time health
insurance guarantee. They are doubtful about the researchers’
trustworthiness in the vaccine trial. Also they declined largely
because of resistance from the significant others. Therefore, the
reasons for declining to enroll in an HIV vaccine trial are seen as a
combination of fears.
The fear of an experimental HIV vaccine on reproductive
intentions could be due to the fact that these informants were
young and had already planned to start families with children
before the trial came in. Despite the information given about the
trial safety, they dared not to postpone having children because of
fear of possible irreversible side effect of the vaccine in
reproduction. However, this fear was raised by more men than
women, implying that women understood that the trial was safe in
their reproductive capacity. On the contrary, previous studies
show that women are concerned about the effect of HIV vaccine
trial on their reproduction [10,12]; and the need to delay
pregnancy during trial had a larger effect on willingness to take
part in the HIV vaccine trials [22].
In this study, the fear of harmful effects from the trial could be
due to concurrent incidents (a colleague vomiting after the trial,
and an experience of losing a sibling, not connected to trial
though) which posed threats to the informants just before they got
the first vaccination. In the first incident, these co-workers
[informant and the volunteer] must have discussed their
participation in the HIV vaccine trial voluntarily. In a previous
study, potential volunteers reported to seek opinions about their
decision to volunteer in the HIV vaccine trial from the significant
others such as co-workers [13]. Thus, the two workers reported
here must have known each other through such interactions and
participation in the recruitment seminars. The informant in the
second incident was seriously worried by death of the sibling.
Mentally, these informants might have been in doubt even before
the incidents, and that the incidents just aggravated their decisions
of not to enroll in the trial. Fear of unknown as portrayed by one of
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viewed as likely to visit the same family because of uncertainty
about vaccine safety. The novelty of the experimental vaccine, as
noted elsewhere [14], can aggravate the fear.
The resistance from the significant others could be associated
with lack of awareness about HIV vaccine trials in the general
population. The significant others believed that, HIV vaccine trials
could affect the informants in different ways. The most important
concern was the possibility that the candidate vaccine could cause
death; death that could break the established social support
networks. This concern may be due in part to the fixed social
support networks in African families [23]. In a previous study
among police officers, respondents significantly stated that they
would share their intent to volunteer in an HIV vaccine trial with
significant others so that they may take care if they suffer from side
effects [20]. Conversely, in the present study, the discouragement
from the parents was the possibility that their sons could die
because of enrolling in the trial and end the dependence chain.
This fear signifies the importance of young men for the aging
parents in a Tanzanian context as stated earlier by potential
volunteers for a phase I and II HIV vaccine trial [13]. Partly, the
fear could also be fuelled by experiences of death of young adults
due to AIDS in sub-Saharan African countries [24]. Thus, the
concerns pointed out by the parents indicate worries of
deliberately losing young adults who would otherwise be
guarantees of support in their old age. Interestingly, more men
consulted parents, and more women consulted sexual partners for
approval to enroll in the trial. This discourse provides a clue on
influences of specific types of significant others on the potential
volunteers in future trials. However, such influence confronts
women in their struggle for own decision to participate in the HIV
prevention strategies.
Limitations
The results of this study cannot be generalised beyond the
context we studied, but can be transferred to similar contexts.
Also, given that almost all those who declined to enroll in the HIV
vaccine trial were interviewed implies that, there was no room for
saturation [25] as would have been the case for a traditional
qualitative sample. The interview sessions reflect the number and
details of the reasons for declining to enroll in the trial provided by
the informants, and most of the informants were interviewed 1–3
months after randomization and withdrawal from the study.
Although, four informants were contacted and interviewed 20–23
months after randomisation and withdrawal from the study, they
used almost the same amount of time during the interview. On the
one hand this delayed contact could have influenced the recalling
of reasons for declining. However, the probing nature of
qualitative interviews enabled the researcher to gain in-depth
description of the stated reasons. Furthermore, to some, the long
period between randomisation and this follow up interview might
have enabled the informants to reflect and recall the key reason(s)
for declining. Nevertheless, we can not tell the impact of this
delayed contact on reasons given from the individual interviews
because some of the reasons given by the four informants were
similar to what earlier informants had shared.
Although it could be difficult to access most people who decided
not to participate in the HIV vaccine trial for such interviews, we
managed to access our study informants through a well established
cohort in the police force. In this cohort, a group of individuals
voluntarilyformeda coregroup toeducate othersaboutHIV,AIDS
and other health related issues which were supported by experts
from the trial team. All informants in this study happened to be part
of the core group, and they remained active in the core group
despite their decision to decline from the trial. Thus, access was not
a problem for those who were still working in Dar es Salaam region.
We could not reach three men who declined because they were
relocated in other work places, outside Dar es Salaam. In addition,
two refused to participate in the study without providing explanations.
As researchers, we were curious to know what their reasons were, but
ethically it was not acceptable to enquire about their reasons.
The interval between randomization and vaccination might
have facilitated the potential volunteers to enquire further advice
from the significant others that lead to changing their decision to
enroll in the trial. Although potential volunteers were informed
from the start to share their decision with the significant others if
they wished to, they abruptly decided to consult them after
randomization. On one hand, it was their ethical right to do so at
any time. However, it would have been wise to perform this
consultation from the beginning to maximize use of the resources.
Also the procedure of giving vaccination 14 days after
randomization that was employed at this site might have facilitated
the informants to change their decision to enroll in the trial at a
later stage after recruitment. However, this could also have led to
self-exclusion of volunteers who were not yet firmly decided on
enrollment despite being recruited by study staff. The trial team
comprised of trained health care providers (Doctors, Nurses, Nurse
Counsellors, Laboratory technologists and Support staff) with
training and Certification in Good Clinical Practice (GCP) or
Good Clinical Laboratory Practice (GCLP). Additionally, Stan-
dard Operating Procedures specific for conducting the HIV
vaccine trial were adhered to. Despite the shortfalls, the knowledge
gained and being shared appears important for the design of future
HIV vaccine trials in similar contexts.
Implications
In this study, informants suggested that HIV vaccine trial
education should target the general population rather than
limiting education to a specific group of individuals. They
emphasized that, the best settings for HIV related education
could be the common meeting places such as recreation centres.
They also highlighted the need to involve significant others,
example relatives of those who enroll in the trial from the onset as
stated by one of the informant:
‘‘In the meetings, if I could come with my close relative of
whom I believe if he or she gets such education and accept,
both we would agree’’ (Informant 13, man).
Retention of randomised volunteers in HIV vaccine trials is
important to maximise use of resources in conducting trials. These
findings call for HIV vaccine trial implementers to consider the
influences of significant others when recruiting volunteers in HIV
vaccine trials and clear the doubts. Also, trial implementers should
encourage extensive discussion about social issues with the
potential volunteers to enhance disclosure of potential barriers
from the surrounding communities. The insurance facts and
personal fears need to be clarified through extensive counselling.
For example, the duration of the vaccination contents in the body
and safety in reproduction continuity should be transparent to
clear the doubts. This study contributes important knowledge for
future recruitment of volunteers for HIV vaccine trials in
Tanzania and in other similar contexts.
Conclusions
This qualitative study illustrates that the main reasons for
declining to enroll in the HIV vaccine trial after randomisation are
Enrolling in HIV Vaccine Trial
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uninformed or poorly informed significant others. We are
witnessing the complexity of decision making within the social
networks in times of doubt. Within these social networks,
informants are bound to share decisions with ones they depend
on for social support. Thus, it is what the informants had doubts
on that impacted on their final decision. The faced resistance from
significant others suggests the need to involve them during the
recruitment of volunteers in the future as suggested by the
informants themselves. In the light of these findings, trial
implementers can oversee possible factors that can influence
retention of those who will volunteer in the future trials.
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